Elixir Medical Corporation Announces Positive First-In-
Results for Three Drug Eluting Coronary Stent Systems
Durable and Bioabsorbable Polymers
New Bioabsorbable Polymer Results Consistent with Excellent Long Term Data from Company’s Durable Polymer Platfor
Enrollment for EXCELLA II Randomized Clinical Trial Completed
September 23, 2009 08:00 AM Eastern Daylight Time
SUNNYVALE, Calif. & SAN FRANCISCO--(EON: Enhanced Online News)--Elixir Medical Corporation, a developer of prod
state-of-the-art medical devices with advanced pharmaceuticals, announced today positive results from three multicenter first-in-ma
NovolimusTM and MyolimusTM eluting coronary stent systems with durable and bioabsorbable polymers. Findings were presented
Transcatheter Cardiovascular Therapeutics (TCT 2009) scientific symposium.
Novolimus Eluting Coronary Stent System with Bioabsorbable Polymer: Nine-Month Clinical and Six-Month Angiogra
Nine-month clinical and six-month angiographic and IVUS results from the first-in-man study of Novolimus eluting coronary stent sy
proprietary bioabsorbable polymer were presented at TCT 2009 by Professor Alexandre Abizaid, M.D., Ph.D. on behalf of the stu
At nine months, the Novolimus eluting coronary stent system demonstrated excellent efficacy and clinical safety with no MACE eve
stent thrombosis. Six-month angiographic and IVUS follow-up demonstrated an in-stent late lumen loss of 0.16 ± 0.23 mm and a v
of 1.6 ± 0.9 percent.
Myolimus Eluting Coronary Stent System with Bioabsorbable Polymer: Six-Month Clinical and Angiographic Results
Six-month clinical, angiographic and IVUS results from the first-in-man study of the Myolimus eluting coronary stent system with the
dose of an ‘olimus’ drug and Elixir’s proprietary bioabsorbable polymer were presented at TCT 2009 by Professor Bernard Witze
Charite Campus Benjamin Franklin, Berlin, Germany on behalf of the study investigators. At the six-month follow-up for 30 patients
non Q-wave myocardial infarctions and one target lesion revasculariz